Barclays PLC Boosts Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Barclays PLC lifted its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 155,338 shares of the biotechnology company's stock after acquiring an additional 8,936 shares during the quarter. Barclays PLC owned 0.20% of Veracyte worth $6,150,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in VCYT. Jones Financial Companies Lllp boosted its holdings in shares of Veracyte by 49.7% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 237 shares during the period. US Bancorp DE boosted its holdings in shares of Veracyte by 57.4% in the 4th quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 647 shares in the last quarter. Principal Securities Inc. grew its position in Veracyte by 34.1% during the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 485 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Veracyte during the 4th quarter valued at $91,000. Finally, Sterling Capital Management LLC grew its stake in shares of Veracyte by 810.2% during the fourth quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock valued at $96,000 after buying an additional 2,155 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VCYT. Craig Hallum started coverage on shares of Veracyte in a research report on Thursday, March 20th. They issued a "buy" rating and a $45.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price objective on shares of Veracyte in a report on Tuesday, February 25th. Stephens reiterated an "overweight" rating and set a $45.00 target price on shares of Veracyte in a report on Wednesday, March 26th. UBS Group lifted their price target on Veracyte from $46.00 to $49.00 and gave the stock a "buy" rating in a research report on Tuesday, February 25th. Finally, StockNews.com cut Veracyte from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $42.60.

Veracyte Stock Performance

NASDAQ:VCYT opened at $32.23 on Friday. The firm has a 50-day simple moving average of $32.25 and a 200-day simple moving average of $37.28. The firm has a market cap of $2.51 billion, a P/E ratio of -214.87 and a beta of 2.03. Veracyte, Inc. has a one year low of $19.16 and a one year high of $47.32.

Veracyte (NASDAQ:VCYT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The firm had revenue of $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. During the same quarter last year, the firm earned ($0.39) EPS. On average, research analysts predict that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.